Literature DB >> 22764241

Striatal dopamine release and genetic variation of the serotonin 2C receptor in humans.

Brian J Mickey1, Benjamin J Sanford, Tiffany M Love, Pei-Hong Shen, Colin A Hodgkinson, Christian S Stohler, David Goldman, Jon-Kar Zubieta.   

Abstract

Mesoaccumbal and nigrostriatal projections are sensitive to stress, and heightened stress sensitivity is thought to confer risk for neuropsychiatric disorders. Serotonin 2C (5-HT(2C)) receptors mediate the inhibitory effects of serotonin on dopaminergic circuitry in experimental animals, and preclinical findings have implicated 5-HT(2C) receptors in motivated behaviors and psychotropic drug mechanisms. In humans, a common missense single-nucleotide change (rs6318, Cys23Ser) in the 5-HT(2C) receptor gene (HTR2C) has been associated with altered activity in vitro and with clinical mood disorders. We hypothesized that dopaminergic circuitry would be more sensitive to stress in humans carrying the Ser23 variant. To test this hypothesis, we studied 54 healthy humans using positron emission tomography and the displaceable D(2)/D(3) receptor radiotracer [(11)C]raclopride. Binding potential (BP(ND)) was quantified before and after a standardized stress challenge consisting of 20 min of moderate deep muscular pain, and reduction in BP(ND) served as an index of dopamine release. The Cys23Ser variant was genotyped on a custom array, and ancestry informative markers were used to control for population stratification. We found greater dopamine release in the nucleus accumbens, caudate nucleus, and putamen among Ser23 carriers, after controlling for sex, age, and ancestry. Genotype accounted for 12% of the variance in dopamine release in the nucleus accumbens. There was no association of Cys23Ser with baseline BP(ND). These findings indicate that a putatively functional HTR2C variant (Ser23) is associated with greater striatal dopamine release during pain in healthy humans. Mesoaccumbal stress sensitivity may mediate the effects of HTR2C variation on risk of neuropsychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22764241      PMCID: PMC3431013          DOI: 10.1523/JNEUROSCI.1260-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  57 in total

1.  RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy.

Authors:  C M Niswender; K Herrick-Davis; G E Dilley; H Y Meltzer; J C Overholser; C A Stockmeier; R B Emeson; E Sanders-Bush
Journal:  Neuropsychopharmacology       Date:  2001-05       Impact factor: 7.853

2.  Automated Talairach atlas labels for functional brain mapping.

Authors:  J L Lancaster; M G Woldorff; L M Parsons; M Liotti; C S Freitas; L Rainey; P V Kochunov; D Nickerson; S A Mikiten; P T Fox
Journal:  Hum Brain Mapp       Date:  2000-07       Impact factor: 5.038

3.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.

Authors:  Joseph A Maldjian; Paul J Laurienti; Robert A Kraft; Jonathan H Burdette
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

4.  Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635.

Authors:  G Bagdy; M Graf; Z E Anheuer; E A Modos; S Kantor
Journal:  Int J Neuropsychopharmacol       Date:  2001-12       Impact factor: 5.176

5.  m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors.

Authors:  G Di Giovanni; V Di Matteo; V La Grutta; E Esposito
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

6.  Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder.

Authors:  B Lerer; F Macciardi; R H Segman; R Adolfsson; D Blackwood; S Blairy; J Del Favero; D G Dikeos; R Kaneva; R Lilli; I Massat; V Milanova; W Muir; M Noethen; L Oruc; T Petrova; G N Papadimitriou; M Rietschel; A Serretti; D Souery; S Van Gestel; C Van Broeckhoven; J Mendlewicz
Journal:  Mol Psychiatry       Date:  2001-09       Impact factor: 15.992

7.  Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations.

Authors:  H Watabe; C J Endres; A Breier; B Schmall; W C Eckelman; R E Carson
Journal:  J Nucl Med       Date:  2000-03       Impact factor: 10.057

8.  Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice.

Authors:  Beatriz A Rocha; Evan H Goulding; Laura E O'Dell; Andy N Mead; Nicole G Coufal; Loren H Parsons; Laurence H Tecott
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

Review 9.  Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.

Authors:  M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2000-03       Impact factor: 6.200

10.  The effects of the selective 5-HT(2C) receptor antagonist SB 242084 on learned helplessness in male Fischer 344 rats.

Authors:  Paul V Strong; Benjamin N Greenwood; Monika Fleshner
Journal:  Psychopharmacology (Berl)       Date:  2008-11-27       Impact factor: 4.530

View more
  20 in total

1.  Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists.

Authors:  Roberta Galeazzi; Luca Massaccesi; Francesco Piva; Giovanni Principato; Emilioano Laudadio
Journal:  J Mol Model       Date:  2014-02-22       Impact factor: 1.810

Review 2.  The activity of the serotonin receptor 2C is regulated by alternative splicing.

Authors:  Stefan Stamm; Samuel B Gruber; Alexander G Rabchevsky; Ronald B Emeson
Journal:  Hum Genet       Date:  2017-06-29       Impact factor: 4.132

3.  Persistent neuropathic pain increases synaptic GluA1 subunit levels in core and shell subregions of the nucleus accumbens.

Authors:  Duo Xu; Chen Su; Hau-Yueh Lin; Toby Manders; Jing Wang
Journal:  Neurosci Lett       Date:  2015-10-22       Impact factor: 3.046

4.  5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice.

Authors:  Vladimir M Pogorelov; Ramona M Rodriguiz; Jianjun Cheng; Mei Huang; Claire M Schmerberg; Herbert Y Meltzer; Bryan L Roth; Alan P Kozikowski; William C Wetsel
Journal:  Neuropsychopharmacology       Date:  2017-03-15       Impact factor: 7.853

5.  Genetic Polymorphisms in the Dopamine Receptor 2 Predict Acute Pain Severity After Motor Vehicle Collision.

Authors:  Yawar J Qadri; Andrey V Bortsov; Danielle C Orrey; Robert A Swor; David A Peak; Jeffrey S Jones; Niels K Rathlev; David C Lee; Robert M Domeier; Phyllis L Hendry; Samuel A Mclean
Journal:  Clin J Pain       Date:  2015-09       Impact factor: 3.442

Review 6.  Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.

Authors:  Leonard L Howell; Kathryn A Cunningham
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Calcium-permeable AMPA receptors in the nucleus accumbens regulate depression-like behaviors in the chronic neuropathic pain state.

Authors:  Yossef Goffer; Duo Xu; Sarah E Eberle; James D'amour; Michelle Lee; David Tukey; Robert C Froemke; Edward B Ziff; Jing Wang
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

8.  Striatal Hypersensitivity During Stress in Remitted Individuals with Recurrent Depression.

Authors:  Roee Admon; Laura M Holsen; Harlyn Aizley; Anne Remington; Susan Whitfield-Gabrieli; Jill M Goldstein; Diego A Pizzagalli
Journal:  Biol Psychiatry       Date:  2014-10-02       Impact factor: 13.382

Review 9.  Frontostriatal Gating of Tinnitus and Chronic Pain.

Authors:  Josef P Rauschecker; Elisabeth S May; Audrey Maudoux; Markus Ploner
Journal:  Trends Cogn Sci       Date:  2015-10       Impact factor: 20.229

10.  Impact of serotonin (5-HT)2C receptors on executive control processes.

Authors:  Luis Pennanen; Marieke van der Hart; Lisa Yu; Laurence H Tecott
Journal:  Neuropsychopharmacology       Date:  2012-12-13       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.